---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-003481"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2022-02-08T23:59:59+00:00"
generated_at: "2026-06-27T10:11:06.404657+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Ensysce Biosciences appoints Lee Rauch to board of directors

## Summary
- Lee Rauch appointed as Class I director effective Feb 8, 2022; term expires at 2022 annual meeting.
- Rauch will serve on Compensation Committee; granted option for 20,000 shares at $1.70 per share.
- Receives annual cash compensation of $7,500, prorated for service through the 2022 annual meeting.
- Rauch is a 40-year industry veteran, former CEO of Viridian Therapeutics and founding member of McKinsey's pharma practice.

## SEC filing metadata
- accession: 0001493152-22-003481
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2022-02-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315222003481/0001493152-22-003481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315222003481/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-003481
- JSON: https://secwatch.observer/filing/0001493152-22-003481.json
- Plain text: https://secwatch.observer/filing/0001493152-22-003481.txt

## Key facts
- Executive change
  Lee Rauch was appointed as Director at Ensysce Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 8, 2022, the Board of Ensysce Biosciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Lee Rauch to its Board of Directors (“Board”), effective immediately (the “New Director”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315222003481/0001493152-22-003481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.